Atherectomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Atherectomy is a minimally invasive, catheter-based endovascular procedure designed to physically remove — rather than compress — atherosclerotic plaque from the inner lining of diseased arteries. It differs fundamentally from angioplasty (balloon dilation) and stenting, which compress or bypass the plaque; atherectomy actually debulks the obstructing material and restores luminal diameter.

The procedure is performed under local anaesthesia with conscious sedation through a small arterial access point — typically the femoral artery in the groin or the radial artery at the wrist. A guide wire is advanced under fluoroscopic (X-ray) guidance to the site of arterial narrowing. An atherectomy catheter — a specialised device carrying a cutting, ablating, or orbital mechanism at its tip — is then tracked to the lesion. Depending on the device type, the catheter either shaves, rotates, orbits, or laser-ablates the plaque. Removed tissue fragments are either collected within the catheter (directional atherectomy) or reduced to particles smaller than 10 microns (laser and rotational systems) that pass harmlessly through the microcirculation.

Atherectomy is most commonly applied in peripheral artery disease (PAD) of the lower limb arteries (superficial femoral, popliteal, tibial) and in complex coronary artery disease — particularly calcified or heavily fibrotic lesions where balloon angioplasty alone is inadequate. The procedure is often combined with balloon angioplasty and drug-coated balloon therapy to optimise the final luminal result and reduce restenosis rates. The entire procedure takes one to two hours, with hospitalisation of one to two days and a return to normal activity within one to two weeks.

Atherectomy is primarily used in peripheral artery disease (PAD) — atherosclerotic narrowing of the arteries supplying the legs and feet — where it addresses intermediate to long-segment stenoses or occlusions of the superficial femoral artery (SFA), popliteal artery, and tibial/peroneal arteries. In PAD, symptoms range from claudication (cramping leg pain on walking) to chronic limb-threatening ischaemia (CLI) with rest pain and tissue loss (ulcers, gangrene). Atherectomy offers plaque removal that may reduce restenosis compared to balloon angioplasty alone, particularly in below-the-knee tibial vessels where stenting is technically challenging.

In the coronary circulation, rotational atherectomy (using the Rotablator system) and orbital atherectomy (Diamondback 360) are used for heavily calcified coronary artery lesions where standard balloon catheters cannot adequately dilate the lesion or where stent deployment would be suboptimal due to underexpansion. Excimer laser coronary atherectomy is indicated for in-stent restenosis (re-narrowing within a previously placed stent), thrombus-containing lesions, and undilatable lesions. Carotid atherectomy is distinguished from carotid endarterectomy (surgical) and is not commonly performed endovascularly due to embolic risks.

Ideal candidates for atherectomy in PAD are patients with symptomatic claudication or chronic limb-threatening ischaemia caused by focal to intermediate-length stenoses or occlusions in the femoropopliteal or infrapopliteal arteries, particularly in the presence of heavily calcified or fibrotic lesions unsuitable for balloon angioplasty alone. Patients with diabetes, who have a higher incidence of long-segment below-knee disease, frequently benefit from atherectomy to preserve tibial vessel patency for wound healing. Pre-procedural CT angiography or duplex ultrasound is performed to characterise lesion morphology and plan device selection.

Contraindications include severely calcified eccentric lesions at bifurcation points (risk of perforation), fresh thrombus (atherectomy is not a thrombectomy device), severe renal impairment that precludes contrast use, uncorrectable coagulopathy, and vessel anatomy precluding safe catheter access. For coronary atherectomy, the lesion must have confirmed calcium on imaging (fluoroscopic calcification, intravascular ultrasound, or optical coherence tomography), and severe left ventricular dysfunction requires careful risk assessment due to the potential for haemodynamic instability during rotablation.

Directional atherectomy (DA) uses a catheter with an eccentric cutting window that shaves plaque from one side of the arterial wall and collects it in a nose cone chamber for removal. The SilverHawk and TurboHawk devices (Medtronic) are the most widely used for peripheral DA. This technique allows precise, directional plaque removal and is preferred for eccentric and fibrocalcific plaques in the SFA and popliteal artery. DA is often combined with drug-coated balloon (DCB) therapy to reduce restenosis rates — published DEFINITIVE AR study data show improved patency with this combination.

Rotational atherectomy uses a diamond-coated burr rotating at 140,000–180,000 RPM (Rotablator, Boston Scientific) to ablate calcified plaque into microparticles. It is the most widely used technique for calcified coronary lesions and facilitates subsequent optimal stent deployment. Orbital atherectomy (Diamondback 360, Cardiovascular Systems Inc.) uses an eccentrically mounted crown that orbits at variable speeds to sand plaque, allowing larger effective ablation diameters. Excimer laser atherectomy uses pulsed 308-nm ultraviolet laser energy to photochemically ablate atherosclerotic tissue and is particularly effective for in-stent restenosis and thrombus-laden lesions. The choice among these modalities depends on lesion location, calcification pattern, vessel diameter, and operator experience. The treating surgeon individualises the chosen technique based on patient anatomy, the extent and nature of the underlying condition, available equipment, and the balance of procedural benefit against risk — a decision made in consultation with the patient following a thorough informed consent discussion covering all available options.

In peripheral artery disease, atherectomy achieves primary patency rates of 70–80% at 12 months for femoropopliteal lesions in selected series, with freedom from target lesion revascularisation (TLR) of approximately 65–75% at one year when combined with drug-coated balloon therapy. The DEFINITIVE AR randomised trial demonstrated significantly improved 12-month patency for directional atherectomy plus DCB compared to DCB alone (84% vs 66%) in calcified femoropopliteal lesions. Limb salvage rates are high — atherectomy contributes to limb preservation in the CLI population by improving tibial artery inflow to allow wound healing.

For coronary rotational atherectomy, the primary goal is lesion preparation to enable optimal stent expansion in calcified lesions rather than standalone treatment. Success rates for stent deployment following rotablation exceed 95%, with final in-lesion residual stenosis typically less than 20%. Compared to balloon angioplasty alone for heavily calcified coronary lesions, stent-assisted rotablation achieves significantly better acute angiographic results and reduced rates of coronary dissection. Patient-reported outcomes include resolution of claudication, improved walking distances, healing of ischaemic ulcers, and avoidance of surgical bypass, with most patients resuming normal activity within two weeks.

Access-site complications include haematoma (2–5%), pseudoaneurysm (0.5–1%), and arteriovenous fistula formation. Arterial perforation or rupture is an uncommon but serious complication of atherectomy (1–2%), particularly in heavily calcified vessels or when the catheter passes eccentrically. Distal embolisation — migration of plaque fragments into smaller distal vessels — occurs in 1–3% of peripheral atherectomy cases and can cause distal limb ischaemia if not managed promptly with aspiration thrombectomy or pharmacological thrombolysis. Embolic filters are routinely used in some protocols.

For coronary rotational atherectomy, specific risks include slow-flow or no-reflow (5–10%), where microembolisation of ablated particles causes microvascular obstruction and transient or sustained ischaemia requiring pharmacological treatment. Coronary spasm, burr entrapment (rare), and periprocedural myocardial infarction are uncommon but recognised events. Restenosis following atherectomy, while reduced compared to balloon angioplasty alone, remains the principal medium-term limitation — approximately 20–35% of peripheral lesions develop clinically significant restenosis requiring re-intervention at two years.

Following peripheral atherectomy, patients are observed for four to six hours post-procedure for access-site haemostasis and distal pulse assessment before discharge. Dual antiplatelet therapy (aspirin plus clopidogrel) is prescribed for one to three months post-procedure to reduce the risk of early thrombotic occlusion. Patients are advised to avoid heavy lifting and strenuous exercise for one to two weeks. Claudication symptoms typically improve progressively over four to six weeks as tissue perfusion normalises. Follow-up duplex ultrasound is performed at one month, six months, and twelve months to monitor patency and identify early restenosis.

For coronary atherectomy patients, monitoring follows standard post-PCI (percutaneous coronary intervention) protocols with troponin measurement at six to twelve hours post-procedure, aspirin and P2Y12 inhibitor dual antiplatelet therapy for twelve months following stent deployment, and clinical cardiology review at one month, six months, and one year. Lifestyle modification — smoking cessation, lipid management with statins, optimal blood pressure and diabetes control, and supervised cardiac rehabilitation — is critical for long-term arterial health and reduces the need for future re-interventions.

Atherectomy in the United States costs between USD 15,000 and 35,000 per session for peripheral arterial disease, depending on the number of vessels treated, the specific device used, and whether concomitant balloon angioplasty or stenting is performed. Coronary rotational atherectomy as part of a complex PCI procedure adds USD 5,000–10,000 to the procedure cost. These figures include catheterisation laboratory fees, disposable devices, contrast media, and hospital stay but may exclude cardiology specialist fees. Insurance coverage in the US is generally available for medically indicated atherectomy, but prior authorisation requirements can delay access.

Patients travelling to internationally accredited hospitals in India, Thailand, or Turkey can access atherectomy for 50–70% less than US private rates. At major JCI-accredited cardiac centres in India (Narayana, Apollo, Fortis), peripheral atherectomy costs approximately USD 4,000–8,000 all-inclusive. Thai hospitals such as Bumrungrad offer comparable procedures at USD 6,000–10,000. These centres use the same Medtronic, Boston Scientific, and other international device systems used globally, operated by interventionists with international training.

Percutaneous transluminal angioplasty (PTA) with balloon dilation — with or without drug-coated balloons — remains the most widely used endovascular treatment for PAD and is appropriate for non-calcified, shorter lesions where atherectomy's plaque-removal advantage is less critical. Drug-eluting stents (DES) and bare-metal stents provide excellent results in femoropopliteal and iliac disease and are durable alternatives to atherectomy-based strategies. Surgical bypass grafting (femoral-popliteal or femoral-tibial bypass using saphenous vein or prosthetic graft) remains the gold standard for long-segment occlusive disease and is appropriate when endovascular therapy has failed or is not anatomically feasible.

For coronary artery disease, plain balloon angioplasty and drug-eluting stent implantation without atherectomy remain the standard for non-calcified lesions. Coronary artery bypass grafting (CABG) is preferred for multi-vessel disease, left main disease, and complex anatomies where percutaneous approaches carry higher risk. Medical management with optimal antiplatelet therapy, statins, antihypertensives, and lifestyle modification is the foundation of treatment for all patients with atherosclerotic vascular disease and may be sufficient for patients with mild to moderate claudication.